Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast

Overview of attention for article published in Frontiers in Molecular Medicine, May 2023

Altmetric Badge

Mentioned by

twitter: 1 X user

Readers on

mendeley: 1 Mendeley

So far, Altmetric has seen 1 X post from an account with 341 followers.

New Research: Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast #MolecularMedicine https://t.co/OfP0Z8LJbq

18 May 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.